Digital Neuro Biomarkers Market Report 2026

The digital neuro biomarkers market size has grown exponentially in recent years. It will grow from $0.95 billion in 2025 to $1.22 billion in 2026 at a compound annual growth rate (CAGR) of 27.5%. The growth in the historic period can be attributed to the rising prevalence of neurological disorders, increasing adoption of wearable devices, growing focus on cognitive assessment, advancements in neuroimaging technologies, and early research in digital biomarker development.

The digital neuro biomarkers market size is expected to see exponential growth in the next few years. It will grow to $3.19 billion in 2030 at a compound annual growth rate (CAGR) of 27.2%. The growth in the forecast period can be attributed to increasing integration of artificial intelligence in neurological diagnostics, growing demand for remote patient monitoring, expansion of tele-neurology services, rising investments in neuroscience research, and development of personalized neurology treatment solutions. Major trends in the forecast period include greater use of cloud-based neurological data analytics, adoption of real-time brain monitoring technologies, expansion of mobile cognitive assessment applications, integration of machine learning in biomarker analysis, and growth of predictive and precision neurology platforms.

The growing emphasis on the early identification and monitoring of neurological disorders is anticipated to drive the expansion of the digital neuro biomarkers market. Early detection and monitoring rely on digital technologies such as wearable devices, mobile applications, and sensors to continuously evaluate neurological function, cognition, and behavior, allowing timely recognition of neurological conditions. This emphasis is strengthening due to public health initiatives and clinical priorities focused on detecting cognitive decline and neurodegenerative diseases before advanced symptoms develop. Digital neuro biomarkers contribute to these initiatives by providing objective, real-time data that enable clinicians and researchers to identify subtle neurological changes and begin early interventions. For example, in 2024, the U.S. Centers for Disease Control and Prevention’s Healthy Brain Initiative reported that neurological disorders impact nearly one billion people worldwide, including about 50 million individuals with epilepsy and 24 million with Alzheimer’s disease. As a result, the rising focus on early detection and monitoring of neurological disorders using digital technologies is fueling the growth of the digital neuro biomarkers market.

Major companies operating in the digital neuro biomarkers market are concentrating on the development of open-access research infrastructure, such as WearGait PD, to support the creation, validation, and regulatory assessment of wearable-based digital neuro biomarkers for neurological disorders. WearGait PD is a regulatory science dataset that offers synchronized wearable sensor and gait data from individuals with Parkinson’s disease and age-matched control subjects, enabling the extraction and evaluation of gait-derived digital biomarkers for monitoring disease progression. For example, in July 2024, the U.S. Food and Drug Administration (FDA), a U.S.-based regulatory authority, released WearGait PD: Wearables Dataset for Gait in Parkinson’s Disease and Age-Matched Controls, an open-access dataset intended to help researchers and industry developers derive and validate digital biomarkers. The dataset contains raw inertial measurement unit (IMU) acceleration and rotational velocity data, insole pressure measurements, and synchronized gait annotations, supporting algorithm testing, metric validation, and the development of wearable sensor-based monitoring solutions.

In January 2023, Cambridge Cognition Holdings PLC, a UK-based developer of digital cognitive assessment tools and brain health solutions, acquired Winterlight Labs Inc. for £7 million (approximately $8.6 million). Through this acquisition, Cambridge Cognition seeks to broaden its digital neuro biomarker portfolio by incorporating Winterlight’s proprietary free-speech analysis technology, strengthening the company’s capabilities to evaluate and monitor cognitive impairment in clinical research and drug development environments. Winterlight Labs Inc. is a Canada-based provider of digital biomarkers that specialize in speech-derived metrics for identifying and tracking cognitive function in neurological disorders.

Major companies operating in the digital neuro biomarkers market are F. Hoffmann-La Roche AG, Merck KGaA, Biogen Inc., Evidation Health Inc., Huma Therapeutics Limited, Altoida Inc, Cogstate Limited, Quibim S.L., Empatica Inc., Linus Health Inc., Cambridge Cognition Holdings plc, Brainomix Limited, Mindstrong Health Inc., Neurotrack Technologies Inc., Feel Therapeutics Inc., BrainCheck Inc., IXICO plc, NeuraMetrix Inc., NeuraLight Ltd., Koneksa Health Inc., Sonde Health Inc., Aural Analytics Inc., Winterlight Labs Inc.

North America was the largest region in the digital neuro biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the digital neuro biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the digital neuro biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs have impacted the digital neuro biomarker market by increasing the cost of importing wearable devices, sensors, and ai-enabled platforms, creating supply chain disruptions for key components. cloud-based and mobile application solutions are particularly affected, with north america and europe seeing higher operational costs due to tariffs on technology imports. despite these challenges, tariffs have encouraged local manufacturing and innovation in sensor and wearable technology, potentially reducing dependency on foreign suppliers and promoting cost-efficient solutions in the long term.

Digital neuro biomarkers are objective and quantifiable physiological and behavioral data gathered through digital technologies such as wearable devices, mobile applications, sensors, and artificial intelligence algorithms to assess brain health, cognitive performance, and the progression of neurological disorders. These biomarkers help enable early detection, continuous tracking, personalized therapies, and better patient outcomes in neurological care. They also aid clinical decision-making, support remote monitoring, advance neuroscience research, and encourage the development of precision neurology.

The primary types of digital neuro biomarkers include wearable devices, mobile applications, sensors, and others. Wearable devices continuously collect neurological and behavioral data to evaluate cognitive, motor, speech, and behavioral functions. Deployment models include cloud-based, on-premises, and hybrid systems. Biomarker categories include cognitive, motor function, speech and language, and behavioral digital biomarkers, used by healthcare companies, providers, payers, and others.

The digital neuro biomarkers market consists of revenues earned by entities through services and products such as wearable brain monitoring devices, mobile cognitive assessment applications, sensor-based data collection platforms, cloud-based neurological data analytics, and artificial intelligence-enabled diagnostic tools. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital neuro biomarkers market also includes sales of software platforms, wearable devices, mobile applications, and sensor-based diagnostic tools. Values in this market are ‘factory gate’ values, that is, the value of goods and services sold by the creators of the goods, whether to other entities (including downstream manufacturers, healthcare providers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.